GOSS today
$11.24-$0.45 (-3.85%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourBearish
15 minSymmetric Triangle
5 minSymmetric Triangle
Daily trend turns down below $8.31
Key levels
Resistance$63.22
Resistance$12.49
Support$11.08
Support$10.03
Latest news & SEC filings
AnalystPiper Sandler kept its Overweight rating on Gossamer Bio (GOSS) and raised its price target to $96 from $4.
AnalystWedbush kept its Neutral rating on Gossamer Bio (GOSS) with a price target of $32.
All GOSS news →About Gossamer Bio
Gossamer Bio is a drug developer in the clinical testing phase, working on an inhaled kinase inhibitor called seralutinib for high blood pressure in the lungs, covering both the arterial form and cases tied to scarring lung disease. It partners with Chiesi to jointly develop and sell the drug, with Gossamer handling U.S. commercialization for those two conditions while Chiesi covers markets elsewhere. The company also has rights to RT234 through an arrangement with Respira Therapeutics.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
Gossamer Bio, Inc. (GOSS)
What Is the Price Target for GOSS?
SEPT Low Target
$5.00
SEPT Mid Target
$61.00
SEPT High Target
$96.00
Analyst Consensus
$61.00
Is GOSS a Buy or Sell Right Now?
Thesis
- •Revenue growing -57.7% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GOSS.
Start Free Trial →Is GOSS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$61.00
17
Moat Score
NONE
0/9
Piotroski Score
-8.7
Altman Z-Score
What Is Smart Money Doing with GOSS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GOSS Growth Story
Revenue YoY
-57.7%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-200%
FCF Growth YoY
-4840.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for GOSS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GOSS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:30:46 | $11.12 | 3,160 | $$35K | BUY |
| 20:25:34 | $11.24 | 2,000 | $$22K | SELL |
| 17:31:20 | $11.59 | 1,300 | $$15K | BUY |
| 16:30:54 | $11.76 | 1,067 | $$13K | SELL |
| 16:29:07 | $11.91 | 1,000 | $$12K | MIDPOINT |
5 dark pool trades shown · $$97K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Gossamer Bio, Inc. (GOSS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GOSS — frequently asked questions
What is GOSS stock price today?
Gossamer Bio, Inc. (GOSS) is at $11.24, down 3.85% (-$0.45) at the Nov 12, 2026 close.
Why is GOSS stock down today?
Nov 11, 2026: Gossamer Bio shares surged 19.77% to close at $11.69, well above the open of $9.76 and near the day's high of $11.94, on heavy volume of 326,096 shares. The move came as the company reported its third-quarter 2026 financial results, after which analysts cut their forecasts, while Piper Sandler maintained an Overweight rating but lowered its price target to $96 and Wedbush kept a Neutral rating with a reduced target of $32.
What is the GOSS price target?
The average analyst price target for GOSS is $61.00, ranging from $5 to $96, based on 4 analysts. Latest: Wedbush maintains on Nov 11, 2026.
What do analysts rate GOSS?
Analyst ratings for GOSS: 1 Buy, 5 Hold, 0 Sell — consensus Hold.
Did GOSS beat earnings?
GOSS last reported on Nov 11, 2026: EPS -$7.36 vs -$3.68 expected — a miss of 100.0%.
Does GOSS pay a dividend?
GOSS does not currently pay a dividend.
What are GOSS support and resistance levels?
Support: $11.08, $10.03, $8.80. Resistance: $12.49, $63.22, $258.40.
What are insiders doing with GOSS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on GOSS?
Nov 11, 2026: Piper Sandler kept its Overweight rating on Gossamer Bio (GOSS) and raised its price target to $96 from $4. · Nov 11, 2026: Wedbush kept its Neutral rating on Gossamer Bio (GOSS) with a price target of $32.